Nagendra N Mishra

Title(s)Associate Adjunct Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harbor-UCLA Medical Center, TorrancePost-Doctoral Fellowship2012Infectious Diseases
    University of Allahabad, India PhD2004Biochemistry
    Collapse Awards and Honors
    American Society for Microbiology2015ICAAC Young Investigator award

    Collapse Overview 
    Collapse Overview
    Dr. Mishra's lab has focused on the following main areas i) lipidomics; ii) proteomics/genomics iii) metabolomics; iv) antibacterial resistance mechanisms; v) interactions of mammalian platelet microbicidal proteins and platelet mediated anti-bacterial host defenses in vivo and in vitro; vi) metabolic pathway drug targets; vii) combinations of antibiotics for preventing the emergence of antibiotic resistance and viii) pathogenesis of endovascular infections. He also discovered the significance of Staphylococcal carotenoid augmented membrane fluidity/rigidity and its implications in resistance to host defense peptides and in vivo virulence in an endocarditis model. Dr. Mishra has pioneered discovering the mechanism of high level of daptomycin resistance in Streptococci. Dr. Mishra has been reviewer of many prestigious scientific journals, academic editors of reputed journals and research grants of international grant agencies. His work has been recognized by a number of publications as well as grants funded by NIH/Merck/Cubist Pharmaceuticals. Dr. Mishra was honored by the American Society for Microbiology with a 2015 ICAAC (Interscience Conference of Antimicrobial Agents and Chemotherapy) Young Investigator Award. This award recognizes early career scientists for research excellence and potential in microbiology and infectious disease. He has contributed more than 50 research articles, reviews and chapters in peer-reviewed journals. He has mentored over 40 undergraduate, graduate, summer students including research staff during the course of his teaching and research career. He has taught undergraduate and graduate level courses of biochemistry, genetics, microbiology/immunology, biotechnology and directed research courses in medicine. He has been also involved in teaching clinical & non clinical courses to clinical and post doc fellows.

    Collapse Research 
    Collapse Research Activities and Funding
    Efficacy of contrafact efficacy of ContraFect lysin CF-301 in the experimental rabbit endocarditis (IE) model due to the MRSA- VISA.
    ContraFect Corporation 022769-01-00Jan 6, 2022 - Sep 1, 2023
    Role: Co-Principal Investigator
    Role of RVT-1701 lysin with standard-of-care antibiotics (SOC) in treatment of experimental MRSA left-sided Endocarditis (IE) in rabbits.
    Roivant Sciences. 022431-01-00Oct 15, 2020 - Oct 14, 2021
    Role: Co-Principal Investigator
    Mechanisms and circumvention of daptomycin resistance in S. mitis
    R01 AI130056-01Sep 1, 2017 - Aug 31, 2023
    Role: Co-Investigator
    Modeling penicillin binding protein inhibition to optimize cationic peptide-beta lactam treatment
    NIH/NIAID R01 AI132627-01Jun 1, 2017 - May 30, 2023
    Role: Co-Investigator
    Mechanisms of Staphylococcal Co-Resistance to Daptomycin and Host Defense Peptide.
    NIH/NIAID R01AI039108-19Jun 1, 2016 - Oct 1, 2018
    Role: Co-Investigator
    Prevention of evolution of high-level daptomycin-resistance (DAP-R) in vitro in strains of Streptococcus mitis by using DAP combination strategies
    Merck 21508-01Jun 15, 2015 - Jun 30, 2016
    Role: Principal Investigator
    Comparison of Linezolid (LNZ) vs. Tedizolid (TDZ) in an experimental murine model of VRE (vancomycin-resistant Enterococci ) bacteremia.
    Merck 21741-01Jun 15, 2015 - Jun 30, 2016
    Role: Principal Investigator
    Cell membrane characteristics of in vitro-selected daptomycin-resistant strains of S. mitis.
    Cubist Pharmaceuticals 21272-01Nov 25, 2013 - Jun 30, 2015
    Role: Principal Investigator
    Cell membrane characteristics predictive of DAP-host defense peptide cross resistance in MRSA.
    20499-01 Cubist PharmaceuticalsNov 25, 2013 - Jun 30, 2015
    Role: Co- Principal Investigator)
    Molecular Mechanisms of Daptomycin Resistance in Enterococci
    NIH/NIAID 1RO1AI093749Dec 1, 2011 - Jun 30, 2016
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Brilacidin, a novel antifungal agent against Cryptococcus neoformans. mBio. 2024 Jul 17; 15(7):e0103124. Diehl C, Pinzan CF, de Castro PA, Delbaje E, García Carnero LC, Sánchez-León E, Bhalla K, Kronstad JW, Kim D-g, Doering TL, Alkhazraji S, Mishra NN, Ibrahim AS, Yoshimura M, Vega Isuhuaylas LA, Pham LTK, Yashiroda Y, Boone C, Dos Reis TF, Goldman GH. PMID: 38916308; PMCID: PMC11253610.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    2. Membrane Phenotypic, Metabolic and Genotypic Adaptations of Streptococcus oralis Strains Destined to Rapidly Develop Stable, High-Level Daptomycin Resistance during Daptomycin Exposures. Antibiotics (Basel). 2023 Jun 21; 12(7). Mishra NN, de Paula Baptista R, Tran TT, Lapitan CK, Garcia-de-la-Maria C, Miró JM, Proctor RA, Bayer AS. PMID: 37508179; PMCID: PMC10376253.
      View in: PubMed   Mentions:
    3. Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance. Antimicrob Agents Chemother. 2023 04 18; 67(4):e0147222. Mishra NN, Abdelhady W, Elsayed AM, Lapitan C, Proctor RA, Rybak MJ, Miro JM, Bayer AS. PMID: 36877026; PMCID: PMC10112159.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    4. Activity of the Lactate Dehydrogenase Inhibitor Oxamic Acid against the Fermentative Bacterium Streptococcus mitis/oralis: Bactericidal Effects and Prevention of Daptomycin Resistance In Vitro and in an Ex Vivo Model. Antibiotics (Basel). 2022 Oct 13; 11(10). Kebriaei R, Bayer AS, Lapitan CK, Rybak MJ, Somerville GA, Mishra NN. PMID: 36290066; PMCID: PMC9598551.
      View in: PubMed   Mentions: 3  
    5. Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus: In Vitro, Ex Vivo, and In Vivo Metrics. Antimicrob Agents Chemother. 2022 01 18; 66(1):e0164921. Mishra NN, Lew C, Abdelhady W, Lapitan CK, Proctor RA, Rose WE, Bayer AS. PMID: 34694870; PMCID: PMC8765261.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    6. β-Lactam-Induced Cell Envelope Adaptations, Not Solely Enhanced Daptomycin Binding, Underlie Daptomycin-β-Lactam Synergy in Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2021 07 16; 65(8):e0035621. Lew C, Mishra NN, Bayer AS, Rose WE. PMID: 34097478; PMCID: PMC8284448.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    7. Cell Membrane Adaptations Mediate β-Lactam-Induced Resensitization of Daptomycin-Resistant (DAP-R) Staphylococcus aureus In Vitro. Microorganisms. 2021 May 11; 9(5). Mishra NN, Bayer AS, Baines SL, Hayes AS, Howden BP, Lapitan CK, Lew C, Rose WE. PMID: 34064631; PMCID: PMC8150363.
      View in: PubMed   Mentions: 5  
    8. Mechanistic Fingerprinting Reveals Kinetic Signatures of Resistance to Daptomycin and Host Defense Peptides in Streptococcus mitis-oralis. Antibiotics (Basel). 2021 Apr 08; 10(4). Yeaman MR, Chan LC, Mishra NN, Bayer AS. PMID: 33918000; PMCID: PMC8068394.
      View in: PubMed   Mentions: 1  
    9. Impact of Bicarbonate on PBP2a Production, Maturation, and Functionality in Methicillin-Resistant Staphylococcus aureus (MRSA). Antimicrob Agents Chemother. 2023 05 01; 65(5). Ersoy SC, Chambers HF, Proctor RA, Rosato AE, Mishra NN, Xiong YQ, Bayer AS. PMID: 33649115; PMCID: PMC8092911.
      View in: PubMed   Mentions: 9     Fields:    
    10. Prolonged Exposure to β-Lactam Antibiotics Reestablishes Susceptibility of Daptomycin-Nonsusceptible Staphylococcus aureus to Daptomycin. Antimicrob Agents Chemother. 2020 08 20; 64(9). Jenson RE, Baines SL, Howden BP, Mishra NN, Farah S, Lew C, Berti AD, Shukla SK, Bayer AS, Rose WE. PMID: 32601160; PMCID: PMC7449200.
      View in: PubMed   Mentions: 9     Fields:    Translation:Cells
    11. Strain-Specific Adaptations of Streptococcus mitis-oralis to Serial In Vitro Passage in Daptomycin (DAP): Genotypic and Phenotypic Characteristics. Antibiotics (Basel). 2020 Aug 15; 9(8). Mishra NN, Tran TT, Arias CA, Seepersaud R, Sullam PM, Bayer AS. PMID: 32824132; PMCID: PMC7460094.
      View in: PubMed   Mentions: 5  
    12. Metabolic changes associated with adaptive resistance to daptomycin in Streptococcus mitis-oralis. BMC Microbiol. 2020 06 15; 20(1):162. Parrett A, Reed JM, Gardner SG, Mishra NN, Bayer AS, Powers R, Somerville GA. PMID: 32539684; PMCID: PMC7296729.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    13. Proteomic and Membrane Lipid Correlates of Reduced Host Defense Peptide. Antibiotics (Basel). 2019 Sep 28; 8(4). Kohler C, Proctor RA, Bayer AS, Yeaman MR, Lalk M, Engelmann S, Mishra NN. PMID: 31569354; PMCID: PMC6963496.
      View in: PubMed   Mentions: 3  
    14. Metabolic interventions for the prevention and treatment of daptomycin non-susceptibility in Staphylococcus aureus. J Antimicrob Chemother. 2019 08 01; 74(8):2274-2283. Reed JM, Gardner SG, Mishra NN, Bayer AS, Somerville GA. PMID: 31074482.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    15. Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model. Antimicrob Agents Chemother. 2019 06; 63(6). Kebriaei R, Rice SA, Stamper KC, Seepersaud R, Garcia-de-la-Maria C, Mishra NN, Miro JM, Arias CA, Tran TT, Sullam PM, Bayer AS, Rybak MJ. PMID: 30962347; PMCID: PMC6535512.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    16. Comparative Efficacies of Linezolid vs. Tedizolid in an Experimental Murine Model of Vancomycin-Resistant Enterococcal (VRE) Bacteremia. Front Med (Lausanne). 2019; 6:31. Abdelhady W, Mishra NN. PMID: 30842947; PMCID: PMC6391330.
      View in: PubMed   Mentions: 3  
    17. Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in Streptococcus mitis and S. oralis. Antimicrob Agents Chemother. 2019 02; 63(2). Tran TT, Mishra NN, Seepersaud R, Diaz L, Rios R, Dinh AQ, Garcia-de-la-Maria C, Rybak MJ, Miro JM, Shelburne SA, Sullam PM, Bayer AS, Arias CA. PMID: 30509945; PMCID: PMC6355606.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    18. Gain-of-Function Mutations in the Phospholipid Flippase MprF Confer Specific Daptomycin Resistance. mBio. 2018 12 18; 9(6). Ernst CM, Slavetinsky CJ, Kuhn S, Hauser JN, Nega M, Mishra NN, Gekeler C, Bayer AS, Peschel A. PMID: 30563904; PMCID: PMC6299216.
      View in: PubMed   Mentions: 38     Fields:    Translation:Cells
    19. Membrane trafficking of the bacterial adhesin GspB and the accessory Sec transport machinery. J Biol Chem. 2019 02 01; 294(5):1502-1515. Spencer C, Bensing BA, Mishra NN, Sullam PM. PMID: 30514759; PMCID: PMC6364773.
      View in: PubMed   Mentions: 4     Fields:    Translation:Cells
    20. Prevention of High-Level Daptomycin-Resistance Emergence In Vitro in Streptococcus mitis-oralis by Using Combination Antimicrobial Strategies. Curr Microbiol. 2018 Aug; 75(8):1062-1067. Zapata B, Alvarez DN, Farah S, Garcia-de-la-Maria C, Miro JM, Sakoulas G, Bayer AS, Mishra NN. PMID: 29651552.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    21. Impact of Multiple Single-Nucleotide Polymorphisms Within mprF on Daptomycin Resistance in Staphylococcus aureus. Microb Drug Resist. 2018 Oct; 24(8):1075-1081. Yang SJ, Mishra NN, Kang KM, Lee GY, Park JH, Bayer AS. PMID: 29381428; PMCID: PMC6200021.
      View in: PubMed   Mentions: 11     Fields:    Translation:Cells
    22. Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs). J Antimicrob Chemother. 2017 08 01; 72(8):2290-2296. Yim J, Smith JR, Singh NB, Rice S, Stamper K, Garcia de la Maria C, Bayer AS, Mishra NN, Miró JM, Tran TT, Arias CA, Sullam P, Rybak MJ. PMID: 28475731; PMCID: PMC5890769.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    23. Perturbations of Phosphatidate Cytidylyltransferase (CdsA) Mediate Daptomycin Resistance in Streptococcus mitis/oralis by a Novel Mechanism. Antimicrob Agents Chemother. 2017 04; 61(4). Mishra NN, Tran TT, Seepersaud R, Garcia-de-la-Maria C, Faull K, Yoon A, Proctor R, Miro JM, Rybak MJ, Bayer AS, Arias CA, Sullam PM. PMID: 28115347; PMCID: PMC5365703.
      View in: PubMed   Mentions: 32     Fields:    Translation:Cells
    24. Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates. J Microbiol. 2017 Feb; 55(2):153-159. Kang KM, Mishra NN, Park KT, Lee GY, Park YH, Bayer AS, Yang SJ. PMID: 28120188; PMCID: PMC6218394.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    25. Dysregulation of mprF and dltABCD expression among daptomycin-non-susceptible MRSA clinical isolates. J Antimicrob Chemother. 2016 08; 71(8):2100-4. Bayer AS, Mishra NN, Cheung AL, Rubio A, Yang SJ. PMID: 27121398; PMCID: PMC4954926.
      View in: PubMed   Mentions: 21     Fields:    Translation:Cells
    26. The role of Staphylococcal carotenogenesis in resistance to host defense peptides and in vivo virulence in experimental endocarditis model. Pathog Dis. 2015 Oct; 73(7). Xiong YQ, Yang SJ, Tong SY, Alvarez DN, Mishra NN. PMID: 26242278; PMCID: PMC4607738.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    27. Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides. Antimicrob Agents Chemother. 2015 Aug; 59(8):4930-7. Bayer AS, Mishra NN, Chen L, Kreiswirth BN, Rubio A, Yang SJ. PMID: 26055370; PMCID: PMC4505294.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    28. A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis. J Infect Dis. 2015 Apr 15; 211(8):1317-25. Reyes J, Panesso D, Tran TT, Mishra NN, Cruz MR, Munita JM, Singh KV, Yeaman MR, Murray BE, Shamoo Y, Garsin D, Bayer AS, Arias CA. PMID: 25362197; PMCID: PMC4402337.
      View in: PubMed   Mentions: 49     Fields:    Translation:AnimalsCells
    29. Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother. 2014 Dec; 58(12):7462-7. Bayer AS, Mishra NN, Sakoulas G, Nonejuie P, Nast CC, Pogliano J, Chen KT, Ellison SN, Yeaman MR, Yang SJ. PMID: 25288091; PMCID: PMC4249560.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    30. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One. 2014; 9(9):e107426. Mishra NN, Bayer AS, Weidenmaier C, Grau T, Wanner S, Stefani S, Cafiso V, Bertuccio T, Yeaman MR, Nast CC, Yang SJ. PMID: 25226591; PMCID: PMC4166420.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    31. Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Clin Infect Dis. 2014 Nov 01; 59(9):1277-80. Munita JM, Mishra NN, Alvarez D, Tran TT, Diaz L, Panesso D, Reyes J, Murray BE, Adachi JA, Bayer AS, Arias CA. PMID: 25107294; PMCID: PMC4271039.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    32. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother. 2013 Nov; 57(11):5658-64. Yang SJ, Mishra NN, Rubio A, Bayer AS. PMID: 24002096; PMCID: PMC3811309.
      View in: PubMed   Mentions: 49     Fields:    Translation:Cells
    33. Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One. 2013; 8(8):e71151. Mishra NN, Yang SJ, Chen L, Muller C, Saleh-Mghir A, Kuhn S, Peschel A, Yeaman MR, Nast CC, Kreiswirth BN, Crémieux AC, Bayer AS. PMID: 23990934; PMCID: PMC3747195.
      View in: PubMed   Mentions: 53     Fields:    Translation:AnimalsCells
    34. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. mBio. 2013 Jul 23; 4(4). Tran TT, Panesso D, Mishra NN, Mileykovskaya E, Guan Z, Munita JM, Reyes J, Diaz L, Weinstock GM, Murray BE, Shamoo Y, Dowhan W, Bayer AS, Arias CA. PMID: 23882013; PMCID: PMC3735187.
      View in: PubMed   Mentions: 85     Fields:    Translation:Cells
    35. Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. PLoS One. 2013; 8(6):e67398. Bertsche U, Yang SJ, Kuehner D, Wanner S, Mishra NN, Roth T, Nega M, Schneider A, Mayer C, Grau T, Bayer AS, Weidenmaier C. PMID: 23785522; PMCID: PMC3681945.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    36. Virulence of endemic nonpigmented northern Australian Staphylococcus aureus clone (clonal complex 75, S. argenteus) is not augmented by staphyloxanthin. J Infect Dis. 2013 Aug 01; 208(3):520-7. Tong SY, Sharma-Kuinkel BK, Thaden JT, Whitney AR, Yang SJ, Mishra NN, Rude T, Lilliebridge RA, Selim MA, Ahn SH, Holt DC, Giffard PM, Bayer AS, Deleo FR, Fowler VG. PMID: 23599317; PMCID: PMC3699000.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    37. Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013 Feb; 57(2):1082-5. Mishra NN, Bayer AS. PMID: 23254419; PMCID: PMC3553710.
      View in: PubMed   Mentions: 56     Fields:    Translation:Cells
    38. Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother. 2013 Jan; 57(1):261-8. Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, Lobos EA, Shamoo Y, Mishra NN, Bayer AS, Murray BE, Weinstock GM, Arias CA. PMID: 23114757; PMCID: PMC3535923.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    39. Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content. PLoS One. 2012; 7(8):e43958. Mishra NN, Bayer AS, Tran TT, Shamoo Y, Mileykovskaya E, Dowhan W, Guan Z, Arias CA. PMID: 22952824; PMCID: PMC3428275.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    40. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis. 2012 Oct; 206(8):1160-7. Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. PMID: 22904338; PMCID: PMC3448966.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    41. Differential Adaptations of Methicillin-Resistant Staphylococcus aureus to Serial In Vitro Passage in Daptomycin: Evolution of Daptomycin Resistance and Role of Membrane Carotenoid Content and Fluidity. Int J Microbiol. 2012; 2012:683450. Mishra NN, Rubio A, Nast CC, Bayer AS. PMID: 22956961; PMCID: PMC3431083.
      View in: PubMed   Mentions: 24  
    42. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2012 Feb; 56(2):838-44. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. PMID: 22123698; PMCID: PMC3264218.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCells
    43. The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides. Infect Immun. 2012 Jan; 80(1):74-81. Yang SJ, Bayer AS, Mishra NN, Meehl M, Ledala N, Yeaman MR, Xiong YQ, Cheung AL. PMID: 21986630; PMCID: PMC3255649.
      View in: PubMed   Mentions: 84     Fields:    Translation:Cells
    44. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011 Sep; 55(9):4012-8. Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, Kreiswirth BN, Bayer AS. PMID: 21709105; PMCID: PMC3165344.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCells
    45. Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob Agents Chemother. 2011 Feb; 55(2):526-31. Mishra NN, Liu GY, Yeaman MR, Nast CC, Proctor RA, McKinnell J, Bayer AS. PMID: 21115796; PMCID: PMC3028772.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCells
    46. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother. 2010 Aug; 54(8):3079-85. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. PMID: 20498310; PMCID: PMC2916340.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCells
    47. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 2009 Nov; 5(11):e1000660. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A. PMID: 19915718; PMCID: PMC2774229.
      View in: PubMed   Mentions: 176     Fields:    Translation:Cells
    48. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009 Jun; 53(6):2312-8. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS. PMID: 19332678; PMCID: PMC2687258.
      View in: PubMed   Mentions: 119     Fields:    Translation:Cells
    Nagendra's Networks
    Concepts (162)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (13)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California